Sunifiram

Sunifiram

SCHEMBL195641

CCC(=O)N1CCN(C(=O)c2ccccc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 1.00
POLB P06746 1/20 0.63
HPGD P15428 1/20 0.59
ALDH1A1 P00352 4/20 0.58
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
ACHE P22303 1/20 0.57
USP2 O75604 1/20 0.57
TSHR P16473 2/20 0.56
ALOX15 P16050 1/20 0.56
HSD17B10 Q99714 1/20 0.56
SIGMAR1 Q99720 1/20 0.56
MAPT P10636 1/20 0.56
KDM4E B2RXH2 1/20 0.55
KCNH2 Q12809 1/20 0.55
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL252026 0.84 HPGD (0.79) BLMPOLBHPGDALDH1A1MEN1
SCHEMBL7129676 0.84 HPGD (0.79) BLMPOLBHPGDALDH1A1MEN1
SCHEMBL7848463 0.84 BLM (0.73) BLMPOLBHPGDALDH1A1MEN1
SCHEMBL12582715 0.83 BLM (0.71) BLMPOLBHPGDALDH1A1MEN1
SCHEMBL7838912 0.83 BLM (0.71) BLMPOLBHPGDALDH1A1KMT2A
SCHEMBL16098566 0.83 BLM (0.71) BLMPOLBHPGDALDH1A1KMT2A
SCHEMBL7838280 0.83 BLM (0.71) BLMPOLBMEN1KMT2A
Hydrochloric Acid SCHEMBL1597472 0.82 HPGD (0.76) BLMPOLBHPGDALDH1A1MEN1
SCHEMBL4293002 0.82 BLM (0.70) BLMHPGDALDH1A1MEN1KMT2A
SCHEMBL24549804 0.82 BLM (0.70) BLMPOLBHPGDALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676470-A2 DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF Ingenious Ingredients, LP (US) 2026-01-14 EP claimed
WO-2024187191-A2 DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF Ingenious Ingredients, LP (US) 2024-09-12 WO claimed
US-20240299484-A1 DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF Ingenious Ingredients, LP 2024-09-12 US claimed
US-20240033269-A1 PPARAXANTHINE-BASED COMPOSITIONS FOR INHIBITING INFLAMMATION, IMPROVING JOINT HEALTH, AND ENHANCING IMMUNE FUNCTION PX ING, LLC 2024-02-01 US claimed
EP-3237903-B1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RES & ENG CO (US) 2020-02-26 EP claimed
EP-3237903-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 EP claimed
EP-3237904-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 EP claimed
US-20160187314-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 US claimed
WO-2016106214-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 WO claimed
WO-2016106211-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 WO claimed
US-20160187315-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 US claimed
US-20260097224-A1 METHODS FOR MODULATING NEUROPLASTICITY AMPA INC (US) 2026-04-09 US disclosed
EP-4676470-A2 DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF Ingenious Ingredients, LP (US) 2026-01-14 EP disclosed
US-20250334522-A1 FEMTO-LEVEL DETECTION OF ANALYTE USING SURFACE ENHANCED RAMAN SCATTERING (SERS) SUBSTRATE AND PROCESS THEREOF KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2025-10-30 US disclosed
US-20240299484-A1 DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF Ingenious Ingredients, LP 2024-09-12 US disclosed
WO-2010098495-A1 IMIDAZOLYLPYRAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-02 WO disclosed
WO-2010098487-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-02 WO disclosed
US-20100130537-A1 CINNAMIDE COMPOUNDS FOR DEMENTIA EISAI R&D MANAGEMENT CO., LTD (JP) 2010-05-27 US disclosed
EP-2181992-A1 POLYCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2010-05-05 EP disclosed
US-20090062529-A1 MULTI-CYCLIC COMPOUNDS EISAI R&D MANAGEMENT CO., LTD., (JP) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130537-A1 CINNAMIDE COMPOUNDS FOR DEMENTIA GRIN1, GRIN2A, GRIN3A BLM 4841/4885POLB 4003/4885HPGD 2992/4885
US-20260097224-A1 METHODS FOR MODULATING NEUROPLASTICITY GABRE, BDNF, GRIN2A BLM 4846/4885POLB 2379/4885HPGD 1638/4885
US-20090062529-A1 MULTI-CYCLIC COMPOUNDS APP, BACE1, PSEN1 BLM 1903/4885POLB 3970/4885HPGD 1319/4885
US-20240299484-A1 DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF CPT1B, PYGM, LPL BLM 4019/4885POLB 2869/4885HPGD 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.